Assume that 1,000 subjects in each age cohort have been followed until age 65, have survived, but have developed ESRD at the rates listed above. Use the template in Exhibit H.2 to calculate the risk differences (i.e., difference in rates), the cumulative incidence in each age group, the total costs of this complication, and the savings that can be attributable to screening.

Age Group	Iu	Is	RD	# ESRD Unscreened	#ESRD Screened	Cost Unscreened ($)	Cost Screened ($)	Savings
25-34	159	192	33			$97,360	$96,085
35-44	80	103	23			$76,098	$77,456
45-54	30	42	12			$56,167	$59,448
55-64	9	14	5			$40,254	$44,334
65+	2	3	1			$27,902	$32,490

THIS IS A MANAGERIAL EPIDEMIOLOGY CLASS FOR MY MBA/HCM- Info below is from the question above that is asks to use info from-

The authors (CDC Diabetes Cost-Effectiveness Group 1998) evaluated screening within different age intervals and reported screening costs and treatment costs for those screened at ages 25-34 ($5,933 and $96,085, respectively), ages 35-44 ($2,629 and $77,456, respectively), ages 45-54 ($1006 and $59,448 respectively)ages 55-64 ($715 and $44,334, respectively) and 65 and older ($524 and $32,490, respectively). Treatment costs for the unscreened in each of the five groups were $97,360, $76,098, $56,167, $40,254 and $27,903, respectively. Use Exhibit H.1 as a template to calculate the incremental treatments costs associated with screening in each of the age groups. The incremental costs are found by subtracting the cost without screening from the cost with screening to see if the resources are best used.

Age Group	Without Screening	With Screening	Incremental Costs
25-34	$97,360	$96,085
35-44	$76,098	$77,456
45-54	$56,167	$59,448
55-64	$40,254	$44,334
65+	$27,902	$32,490